Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viaskin PT Safety and Immunogenicity in Healthy Adults
NCT03035370Phase 1Completed
- Sponsor
- DBV Technologies
- Start
- Sep 2016
- Primary completion
- Apr 2018
- Modality
- Vaccines & Immunotherapeutics, Device-based Delivery
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Viaskin PT in pertussis (3 arms), sponsored by DBV Technologies. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Sep 2016; status: completed.
02
Drugs
Viaskin PT
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT03035370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03035370.